에 대한 최신 뉴스 ImmuCell (NASDAQ:ICCC) 주식

ImmuCell

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

PriceSmart

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ICCC

KRUS

MANU

PSMT

수요일 오전(미 동부 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:

수요일 주목해야 할 주식: 맨체스터 유나이티드, 프라이스스마트, 쿠라 스시 그리고 2종목

ImmuCell Corp

- ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the first quarter of 2025.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2025</td>
<td>2024</td>
<td>$ Increase</td>
<td>% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended March 31,</td>
<td>$8.1 million</td>
<td>$7.3 million</td>
<td>$0.8 million</td>
<td>11%</td>
</tr>
<tr>
<td>During the Six-Month Periods Ended March 31,</td>
<td>$15.8 million</td>
<td>$12.4 million</td>
<td>$3.5 million</td>
<td>28%</td>
</tr>
<tr>
<td>During the Twelve-Month Periods Ended March 31,</td>
<td>$27.3 million</td>
<td>$21.3 million</td>
<td>$6.0 million</td>
<td>28%</td>
</tr>
</tbody>
</table>
</figure>
 During the first quarter of 2025, the Company recorded its all-time quarterly sales record, exceeding the previous all-time high mark set during the fourth quarter of 2024 by 4%. The strong sales during the first quarter of 2025 helped, in part, reduce the backlog of orders to $4.0 million as of March 31, 2025, from $4.4 million as of December 31, 2024. Sales recorded during both the six-month and twelve-month periods ended March 31, 2025 also set all-time records for those periods.

Guidance

ImmuCell Preliminary Q1 2025 Revenue Of $8.1M Up From $7.3M YoY; Reduced The Backlog Of Orders To $4M As Of March 31, 2025, From $4.4M As Of December 31, 2024

Management

ImmuCell Hires Timothy Fiori As CFO

General

ImmuCell Initiates Investigational Product Use Of Re-Tain

ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) reported quarterly earnings of $0.06 per share. This is a 140 percent increase over losses of $(0.15) per share from the same period last year. The company reported $7.75 million in sales this quarter. This is a 52.10 percent increase over sales of $5.10 million the same period last year.

ImmuCell Q4 EPS $0.06 Up From $(0.15) YoY, Sales $7.75M Up From $5.10M YoY

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 116.2% to $8.8 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares moved upwards by 70.57% to $0.23. The company's market cap stands at $7.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) shares rose 25.0% to $3.6. The market value of their outstanding shares is at $143.8 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock moved upwards by 22.89% to $0.74. The market value of their outstanding shares is at $1.5 million. </li>
<li>Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) stock rose 17.05% to $5.56. The company's market cap stands at $309.2 million. </li>
<li>Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) shares increased by 15.83% to $122.51. The market value of their outstanding shares is at $5.9 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares decreased by 61.5% to $3.0 during Monday's pre-market session. The company's market cap stands at $182.5 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock fell 14.6% to $2.4. The company's market cap stands at $27.6 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) stock decreased by 11.94% to $4.5. The company's market cap stands at $40.1 million. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares declined by 10.99% to $2.27. The company's market cap stands at $63.6 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) stock fell 10.93% to $1.06. The market value of their outstanding shares is at $34.7 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock declined by 10.18% to $0.1. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AXSM

BACK

BDRX

CYTH

FHTX

GDTC

MBOT

OCEA

OMGA

PLRX

SLDB

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) shares rose 92.1% to $4.61 during Tuesday's pre-market session. The company's market cap stands at $28.8 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock rose 55.15% to $0.43. The company's market cap stands at $5.3 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares moved upwards by 25.65% to $1.91. The market value of their outstanding shares is at $26.1 million. </li>
<li>Achilles Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) shares increased by 20.53% to $1.35. The market value of their outstanding shares is at $57.6 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rose 14.15% to $1.21. The company's market cap stands at $144.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock increased by 13.3% to $4.6. The market value of their outstanding shares is at $94.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares declined by 23.3% to $0.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) stock decreased by 19.35% to $3.21. The market value of their outstanding shares is at $178.5 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock fell 18.23% to $0.52. The company's market cap stands at $23.1 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) stock decreased by 12.36% to $4.4. The company's market cap stands at $39.2 million. </li>
<li>Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) stock declined by 12.34% to $12.01. The market value of their outstanding shares is at $420.3 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) shares fell 12.34% to $0.42. The company's market cap stands at $23.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHL

AZTR

DBVT

EVAX

HCWB

IVVD

KAPA

ORKA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced that it has settled an insurance claim covering some of the losses incurred from production contamination events.
The Company settled a long outstanding insurance claim related to previously disclosed contamination events in its production process incurred from late 2022 through April of 2024. The Company has accepted a settlement in the amount of $426,587, which is in addition to the $250,000 that was paid on this claim and recognized for financial statement purposes during the third quarter of 2023.

Legal

ImmuCell Settles Insurance Claim For $426K Covering Production Contamination Losses, Adding To $250K Paid In Q3 2023

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2024</td>
<td>2023</td>
<td>$ Increase</td>
<td colspan="1">% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended December 31,</td>
<td>$7.8 million</td>
<td>$5.1 million</td>
<td>$2.7 million</td>
<td>52%</td>
</tr>
<tr>
<td>During the Years Ended December 31,</td>
<td>$26.5 million</td>
<td>$17.5 million</td>
<td>$9.0 million</td>
<td>52%</td>
</tr>
</tbody>
</table>
</figure>
 During the three-month period ended December 31, 2024, annualized production output was approximately 103% of the Company's estimated full capacity of approximately $30 million per year. This production output helped reduce the backlog of orders to approximately $4.4 million as of January 1, 2025 from approximately $9.4 million as of January 1, 2024. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of peak calving season during the first quarter.

Reported Earlier, ImmuCell Preliminary Q4 Sales Of $7.8M (+52% YoY) and Fiscal 2024 Of $26.5M (+52% YoY), Driven by Increased Production

ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) reported quarterly losses of $(0.09) per share. This is a 25 percent increase over losses of $(0.12) per share from the same period last year. The company reported $6.01 million in sales this quarter. This is a 11.40 percent increase over sales of $5.40 million the same period last year.

ImmuCell Q3 GAAP EPS $(0.09) Up From $(0.12) YoY, Sales $6.01M Up From $5.40M YoY

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2024</td>
<td>2023</td>
<td colspan="2">$ Increase</td>
<td colspan="1">% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended September 30,</td>
<td>$6.0 million</td>
<td>$5.4 million</td>
<td colspan="2">$615,000</td>
<td>11%</td>
</tr>
<tr>
<td>During the Nine-Month Periods Ended September 30,</td>
<td>$18.7 million</td>
<td>$12.4 million</td>
<td colspan="2">$6.4 million</td>
<td>51%</td>
</tr>
<tr>
<td>During the Twelve-Month Periods Ended September 30,</td>
<td>$23.8 million</td>
<td>$16.3 million</td>
<td colspan="2">$7.6 million</td>
<td>46%</td>
</tr>
</tbody>
</table>
</figure>
 During the three-, nine- and twelve-month periods ended September 30, 2024, annualized production output was approximately 73%, 81% and 77%, respectively, of the Company's estimated full capacity of approximately $30 million per year.
As of September 30, 2024, the backlog of orders aggregated approximately $7.3 million. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of the first quarter calving season.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.

ImmuCell Announces Preliminary Q3 Revenue Of $6M Up From $5.4M YoY

ImmuCell Sees Q2 $(0.20) Down From $(0.18) YoY; Product Sales $5.473M Up From $3.533M YoY

Comments

ImmuCell

뉴스

에 대한 최신 뉴스 ImmuCell (NASDAQ:ICCC) 주식

수요일, 7월 10, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌